GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Net Income

Biolife Sciences (Biolife Sciences) Net Income : $-2.68 Mil (TTM As of May. 2008)


View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Biolife Sciences's Net Income for the three months ended in May. 2008 was $-0.84 Mil. Its Net Income for the trailing twelve months (TTM) ended in May. 2008 was $-2.68 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Biolife Sciences's Earnings per Share (Diluted) for the three months ended in May. 2008 was $-168.40.


Biolife Sciences Net Income Historical Data

The historical data trend for Biolife Sciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Net Income Chart

Biolife Sciences Annual Data
Trend Nov04 Nov05 Nov06 Nov07
Net Income
-0.02 -1.51 -0.29 -2.05

Biolife Sciences Quarterly Data
Nov04 Feb05 May05 Aug05 Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08 May08
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 -0.36 -1.03 -0.45 -0.84

Biolife Sciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Biolife Sciences's Net Income for the fiscal year that ended in Nov. 2007 is calculated as

Net Income(A: Nov. 2007 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.046+0+0+0
=-2.05

Biolife Sciences's Net Income for the quarter that ended in May. 2008 is calculated as

Net Income(Q: May. 2008 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.842+0+0+0
=-0.84

Net Income for the trailing twelve months (TTM) ended in May. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolife Sciences  (OTCPK:BLFE) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Biolife Sciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in May. 2008 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Biolife Sciences Net Income Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolife Sciences (Biolife Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052
Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.
Executives
Arthur Viola director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired 09-15-2020